Safety Reading Notes

Read safety context beside the research guide.

The THC and appetite/metabolic outcomes review source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 23570087

PubMed For Dummies Article

THC and appetite/metabolic outcomes review Evidence Review: the long-form source walk-through

Quick read
  • THC and appetite/metabolic outcomes review currently has 10 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 23570087
  • The evidence classes most visible in the row language are insufficient (8), and preliminary human (2). PMID 10575285
  • The study-design language most visible in the row language is Narrative or expert review (6), Human clinical study (1), Meta-analysis or systematic evidence synthesis (1), and other mapped categories (1). PMID 12608509
  • The repeated topics are Appetite and metabolic outcomes (10), which tells the reader where to start opening PubMed and DOI links. PMID 29670357

Start with the research question

THC and appetite/metabolic outcomes review is built from 10 source-backed evidence row(s) and 10 research source(s). The current evidence classes read as insufficient (8), and preliminary human (2), and the study-design language most often reads as Narrative or expert review (6), Human clinical study (1), Meta-analysis or systematic evidence synthesis (1), and other mapped categories (1). PMID 23570087

The row-level question is not simply whether THC and appetite/metabolic outcomes review is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are Appetite and metabolic outcomes (10). PMID 16849753

Human evidence 2 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 16849753

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 29400010

Mechanistic evidence 0 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 26929669

Limits and uncertainty 8 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 15050664

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 9208884

Where this page has the most source density

The largest bucket surfaced for this page is Appetite and metabolic outcomes: insufficient. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is Appetite and metabolic outcomes: preliminary human, which gives readers another way to see what the literature repeatedly circles. PMID 23570087

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 16849753

Bucket chapters: what the literature is circling

Appetite and metabolic outcomes: insufficient

8 research sources 8 rows (488-496) Evidence class: insufficient

This bucket summarizes source-backed rows focused on Appetite and metabolic outcomes: insufficient. It currently draws from 8 research source(s), so the exact study type matters. PMID 23570087

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 23570087

  • Evidence row 488

    THC studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite or metabolic outc... PMID 23570087

  • Evidence row 496

    THC studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite or metabolic outc... PMID 9208884

Appetite and metabolic outcomes: preliminary human

2 research sources 2 rows (492, 497) Evidence class: preliminary human

This bucket summarizes source-backed rows focused on Appetite and metabolic outcomes: preliminary human. It currently draws from 2 research source(s), so the exact study type matters. PMID 16849753

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 16849753

  • Evidence row 492

    THC studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite or metabolic outco... PMID 16849753

  • Evidence row 497

    THC studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: appetite or metabolic outcomes). PMID 31595793

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (2 row(s)), mechanistic evidence (0 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 23570087

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 16849753

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 31595793
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 23570087
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 10575285

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 23570087

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 16849753

Source-reading checklist for THC and appetite/metabolic outcomes review

  1. Open the linked PubMed or DOI record. PMID 12608509
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 29670357
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 16849753
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 29400010
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 26929669

Source Notes

THC and appetite/metabolic outcomes review source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 488

    THC studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite or metabolic outcomes). PMID 23570087

    Evidence class: insufficient; Study design: Narrative or expert review. Source: [Dronabinol (delta9-tetrahydrocannabinol) in long-term treatment. Symptom control in patients with multiple sclerosis and spasticity, neuropathic pain, loss of appetite and cachexia].
  2. Evidence row 489

    THC studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite or metabolic outcomes). PMID 10575285

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cancer cachexia and cannabinoids.
  3. Evidence row 490

    THC studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite or metabolic outcomes). PMID 12608509

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Orexigenic and anabolic agents.
  4. Evidence row 491

    THC studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite or metabolic outcomes). PMID 29670357

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer.
  5. Evidence row 492

    THC studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: appetite or metabolic outcomes). PMID 16849753

    Evidence class: preliminary human; Study design: Human clinical study. Source: Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group.
  6. Evidence row 493

    THC studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: appetite or metabolic outcomes). PMID 29400010

    Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Systematic review and meta-analysis of cannabinoids in palliative medicine.
  7. Evidence row 494

    THC studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite or metabolic outcomes). PMID 26929669

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS.
  8. Evidence row 495

    THC studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: appetite or metabolic outcomes). PMID 15050664

    Evidence class: insufficient; Study design: Systematic review. Source: Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome.
  9. Evidence row 496

    THC studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite or metabolic outcomes). PMID 9208884

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The cancer cachexia syndrome.
  10. Evidence row 497

    THC studied for Appetite and metabolic outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: appetite or metabolic outcomes). PMID 31595793

    Evidence class: preliminary human. Source: The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot Study.